| Literature DB >> 34306129 |
Bita Geramizadeh1,2, Farzaneh Bozorg-Ghalati2,3, Firoozeh Jafari2, Mitra Mirzai2, Zahra Jowkar2.
Abstract
BACKGROUND &Entities:
Year: 2021 PMID: 34306129 PMCID: PMC8298054 DOI: 10.30699/IJP.2021.131467.2462
Source DB: PubMed Journal: Iran J Pathol ISSN: 1735-5303
Characteristics of antibodies used in immunohistochemistry
| Antibodies | Company | Clone | Dilution |
|---|---|---|---|
| MLH1 | Masterdiagnostica | MAD-000726QD-3 | Pre-diluted |
| MSH2 | Zytomed | MSG031 | Pre-diluted |
| MSH6 | Masterdiagnostica | MAD-000635QD-3 | Pre-diluted |
| PMS2 | Masterdiagnostica | MAD-000681QD-3 | Pre-diluted |
Fig. 1Sections show positive nuclear staining in a case of colorectal adenocarcinoma which means stable and normal MLH 2. (IHC, MLH2 X 250)
Fig. 2Microsatellite analysis. Capillary electrophoresis data show stability (MSS) and instability (MSI-L & MSI-H) of STR markers
Demographic findings in 35 colon cancer cases suspicious to microsatellite instability
| Characteristics | Findings | |
|---|---|---|
|
| 34 cases | |
|
| 14/20 (41%/59%) | |
|
| 24-88 (54.79±16.62) | |
|
| Cecum | 6(17.6%) |
| Cecum and Ascending colon | 1(2.9%) | |
| Ascending colon | 10 (29%) | |
| Hepatic flexure | 1(2.9%) | |
| Transverse colon | 2(5.8%) | |
| Splenic Flexure | 1(2.9%) | |
| Descending colon | 2(5.8%) | |
| Sigmoid | 6(17.6%) | |
| Recto-sigmoid | 3 (8.8%) | |
| rectum | 2 (5.8%) | |
|
| Well differentiated adenocarcinoma | 16 (47%) |
| Moderately differentiated adenocarcinoma | 5 (14.7%) | |
| Poorly differentiated adenocarcinoma | 13 (38.2%) | |
| Mucinous production | 4(11.4%) | |
| Medullary type | 4(11.4%) | |
|
| 3-13 cm (5 ±3.2) | |
|
| I | 4 (11.4%) |
| IIA | 24(68.5%) | |
| IIB | 0 | |
| IIC | 1 (2.9%) | |
| IIIA | 1(2.9%) | |
| IIIB | 3 (8.8%) | |
| IIIC | 1(2.9%) | |
| IV | 0 | |
|
| 11(32.3%) | |
|
| 12(35.2%) | IHC: 8(23.5%) |
|
| 9 | |
|
| 13(25.7%) | IHC: 26 (76.5%) |
MSI=Microsatellite instability
MSS= Microsatellite stability
Microsatellite instability according to individual marker by immunohistochemistry
| Markers | Percentage of loss |
|---|---|
|
| 6 (17.6%) |
|
| 1 (2.9%) |
|
| 2 (5.8%) |
|
| 6 (17.6%) |
Microsatellite instability according to individual marker by immunohistochemistry
| Markers | Percentage of loss |
|---|---|
| MLH1+PMS2 | 4(11.7%) |
| MLH1+MSH6 | 1 (2.9%) |
| MLH1+MSH6+PMS2 | 1(2.9%) |
| MSH2 alone | 1(2.9%) |
| PMS2 alone | 1(2.9%) |
Microsatellite instability and mutation according to individual gene by DNA sequencing
| Gene | Percentage of Mutant |
|---|---|
| NR21 | 10(29.4%) |
| NR24 | 5(14.7%) |
| NR27 | 16(47%) |
| BAT 25 | 9(26.4%) |
| BAT 26 | 4(11.7%) |
Comparison of different clinicopathologic characteristics between MSS and MSI cases
| MSS | MSI-L | MSI-H | MSI | P-value | ||
|---|---|---|---|---|---|---|
|
|
|
|
|
| 4 | 0.00086 |
|
|
|
|
| 17 | ||
|
| <50 | 3 | 4 | 5 | 9 | 0.24 |
| >50 | 10 | 5 | 7 | 12 | ||
|
|
|
|
|
| 12 | 0.53 |
|
|
|
|
| 2 | 0.25 | |
|
|
|
|
| 7 | 0.23 | |
|
| <5 cm | 8 | 6 | 2 | 8 | 0.18 |
| >5 cm | 5 | 3 | 10 | 13 | ||
|
| I | 1 | 2 | 1 | 3 | 0.56 |
| IIA | 10 | 5 | 10 | 15 | 0.7 | |
| IIB | 0 | 0 | 0 | 0 | - | |
| IIC | 1 | 0 | 0 | 0 | 0.19 | |
| IIIA | 0 | 0 | 0 | 1 | 0.42 | |
| IIIB | 1 | 1 | 1 | 2 | 0.85 | |
| IIIC | 0 | 1 | 0 | 1 | 0.42 | |
| IV | 0 | 0 | 0 | 0 | - | |
|
|
|
|
|
| 8 | 0.18 |
|
|
|
|
| 4 | 0.36 | |
|
|
|
|
| 7 | 0.87 | |
|
|
|
|
| 4 | 0.09 | |
|
|
|
|
| 4 | 0.031 | |
|
| 0 | 4 | 7 | 11 | 0.0003 | |
|
| 5 | 3 | 3 | 6 | 0.5 | |